Skip to main content

Individual Drug Analyses

This page contains a complete list of all FDA analyses conducted in the Sentinel System from the start of Mini-Sentinel in 2009 to the present. 

The table below is organized at the individual analysis level (e.g., Level 1, Level 2, Query Builder, protocol-based assessment, etc.). It is designed to support searches for a specific analysis. 

Alternatively, the Drug Studies table groups together related analyses that FDA conducted to address a safety concern, or set of related safety concerns. The Drug Studies page also provides important background information and describes the regulatory impact.

Note: The appearance of a drug in a Sentinel study does not mean that FDA has concluded that a causal relationship exists between the drug and the health outcome of interest. Patients and healthcare providers should refer to FDA.gov for further information about drug safety.

FDA Sentinel Analyses from ARIA and Other Sentinel Data Sources

Title Medical Product Outcomes Date
Outpatient Utilization of COVID-19 Treatments Under Emergency Use Authorization (EUA): A Simplified Descriptive Analysis for Paxlovid and other EUA Drugs
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
bebtelovimab,
casirivimab imdevimab,
molnupiravir,
nirmatrelvir and ritonavir,
remdesivir
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: An Updated Descriptive Analysis
Descriptive
mometasone sinus implant
Characterization of Dispensing Patterns of Baricitinib, Ritlecitinib, and Upadacitinib in Patients with Alopecia, Crohn's Disease, Ulcerative Colitis, and Inflammatory Bowel Disease: A Descriptive Analysis
Descriptive
baricitinib,
ritlecitinib,
upadacitinib
Utilization of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis
TriNetX Analysis
non-insulin antidiabetics
Demographic Characteristics of Incident Users of Selected Non-Insulin Antidiabetics in TriNetX: A Descriptive Analysis
TriNetX Analysis
non-insulin antidiabetics
Clinical Characteristics of Incident Users of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) in TriNetX: A Descriptive Analysis
TriNetX Analysis
glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Utilization of Hormonal Contraceptives Following Live-Birth or Stillbirth Delivery: A Descriptive Analysis
Descriptive
combined hormonal contraceptives (CHCs),
progestin-only contraceptives (POCs)
Risk of Severe Hyperglycemia Following Systemic Corticosteroids and Azithromycin Use in COVID-19 Patients with Type 2 Diabetes: A Sequential Surveillance Analysis
Prospective Sequential Inferential
azithromycin,
corticosteroids
severe hyperglycemia
Corticosteroid Utilization Patterns in Hospitalized Patients With and Without a COVID-19 Diagnosis in TriNetX: A Descriptive Analysis
TriNetX Analysis
Occurrence of Absolute Neutrophil Count (ANC) Monitoring and Neutropenia Following Clozapine Use in Patients from Sentinel Data Partners that Curate ANC Laboratory Results: A Descriptive Analysis
Descriptive
adherence to absolute neutrophil count (ANC) monitoring
neutropenia
Occurrence of Absolute Neutrophil Count (ANC) Monitoring, ANC Laboratory Results, and Neutropenia Following Clozapine Use: A Descriptive Analysis
Descriptive
adherence to absolute neutrophil count (ANC) monitoring
neutropenia
Characterization of Users of Inclisiran in TriNetX: A Descriptive Analysis
TriNetX Analysis
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Third Descriptive Analysis
Descriptive
brodalumab,
guselkumab,
risankizumab,
tildrakizumab
Clozapine Use: First Descriptive Analysis
Descriptive
Clozapine Use: Second Descriptive Analysis
Descriptive
Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: First Descriptive Analysis
Descriptive
adherence to absolute neutrophil count (ANC) monitoring
Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: Second Descriptive Analysis
Descriptive
adherence to absolute neutrophil count (ANC) monitoring
Adherence to Absolute Neutrophil Count (ANC) Monitoring Recommendations Following Clozapine Use: Third Descriptive Analysis
Descriptive
adherence to absolute neutrophil count (ANC) monitoring
Rates of Nervous System Disorders Following Bortezomib Use in Patients: A Descriptive Analysis
Descriptive
Cancer Rates Among Individuals with Loop Diuretics Exposure: A Descriptive Analysis
Descriptive
bumetanide,
loop diuretics
Utilization of Valsartan: A Descriptive Analysis
Descriptive
Utilization of Risankizumab and Comparator Products: A Descriptive Analysis
Descriptive
brodalumab,
guselkumab,
ixekizumab,
risankizumab,
secukinumab,
tildrakizumab,
ustekinumab
Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis
Descriptive
famotidine,
proton pump inhibitors,
single-agent H2 receptor antagonists
Characterization of Users of Atogepant in TriNetX: A Descriptive Analysis
TriNetX Analysis
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: A Descriptive Analysis
Descriptive
Trends in Single-Dose Doxycycline for Lyme Disease Prophylaxis in the United States: An Updated Descriptive Analysis
Descriptive
Trends in Healthcare Encounters with Evidence of Disorders Related to the Use, Abuse, or Dependence of Cannabis, Cocaine, or Alcohol: A Descriptive Analysis
Descriptive
alcohol,
cannabis,
cocaine
substance use disorder
Trends in Healthcare Encounters with Evidence of Poisoning by Cannabis, Cocaine, Alcohol, Heroin, or Benzodiazepines: A Descriptive Analysis
Descriptive
alcohol,
benzodiazepines,
cannabis,
cocaine,
heroin
Characteristics of Patients with Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis, Cocaine, Alcohol, Heroin, or Benzodiazepines: A Descriptive Analysis
Descriptive
alcohol,
benzodiazepines,
cannabis,
cocaine,
heroin
poisoning
substance use disorder
Characteristics of Patients with Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis: A Descriptive Analysis
Descriptive
poisoning
substance use disorder
Trends in Healthcare Encounters Involving Disorders or Poisoning Related to Cannabis, Stratified by the Legality Status of Cannabis by State and Territory: A Descriptive Analysis
Descriptive
poisoning
substance use disorder
Outcome Monitoring Following Guselkumab Use: A Signal Identification and Self-Controlled Risk Interval Analysis
Signal Identification
Utilization of Methotrexate: A Descriptive Analysis
Descriptive
Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Second Descriptive Analysis
Descriptive
Counts and Characteristics of Local Anesthetic Toxicity
Summary Table
anesthetic toxicity
Utilization of Products with Labeling Changes Related to Pregnancy Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Descriptive
products with labeling changes related to pregnancy
Outcome Monitoring Following Risankizumab Use: A Signal Identification Analysis
Signal Identification
signal identification
Outcome Monitoring Following Risankizumab Use: A Supplemental Signal Identification Analysis
Signal Identification
signal identification
Outcome Monitoring Following Guselkumab Use: A Signal Identification Analysis
Signal Identification
guselkumab,
risankizumab
Counts and Characteristics of Individuals with Prurigo Nodularis and Other Dermatologic Conditions: A Descriptive Analysis
Descriptive
prurigo nodularis
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Updated Interrupted Time Series Analysis
Retrospective Inferential
Trends in Healthcare Utilization During the COVID-19 Pandemic: A Propensity Score Matched and Stratified Analysis in the Sentinel Distributed Database
Retrospective Inferential
ACE inhibitors,
beta blockers
Trends in Healthcare Utilization During the COVID-19 Pandemic: A Propensity Score Matched and Stratified Analysis in Merative™ MarketScan® Research Databases
Retrospective Inferential
ACE inhibitors,
beta blockers
Characteristics and Drug Utilization in Dabigatran, Rivaroxaban, and Apixaban Initiators Aged 64 or Younger: A Descriptive Analysis
Descriptive
apixaban,
dabigatran,
rivaroxaban
Thromboembolic Stroke, Intracranial Hemorrhage, Gastrointestinal Bleeding, and Major Extracranial Bleeding Following Apixaban, Dabigatran, and Rivaroxaban Use in Patients Aged 64 Years and Younger with Atrial Fibrillation: An Inverse Probability of Treatment Weighting Analysis
Retrospective Inferential
apixaban,
dabigatran,
rivaroxaban
gastrointestinal bleeding
intracranial hemorrhage
major extracranial hemorrhage
thromboembolic stroke
Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: An Updated Descriptive Analysis
Descriptive
Characteristics and Drug Utilization in Pregnant Patients With COVID-19: A Propensity Score Matched Analysis
Retrospective Inferential
Risk of Adverse Maternal Health Outcomes Among Pregnant Patients With and Without COVID-19: A Propensity Score Matched Analysis
Retrospective Inferential
adverse maternal outcomes
Risk of Adverse Neonatal Health Outcomes Among Pregnant Patients With and Without COVID-19: A Propensity Score Matched Analysis
Retrospective Inferential
adverse neonatal outcomes
Utilization of Dupilumab: A Descriptive Analysis
Descriptive
Duration of Follow Up for New Molecular Entities Approved in 2017: Third Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2018: Second Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2019: Second Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2020: First Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2021: First Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Prevalence of Selected Conditions Among Individuals with Childbearing Potential: A Descriptive Analysis
Descriptive
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Obesity: A Descriptive Analysis
Descriptive
glucagon-like peptide-1 (GLP-1) receptor agonists
intentional self-harm
Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes: An Inverse Probability of Treatment Weighting Analysis
Retrospective Inferential
glucagon-like peptide-1 (GLP-1) receptor agonists
intentional self-harm
Utilization of Methotrexate: A Descriptive Analysis in TriNetX
TriNetX Analysis
Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis
Descriptive
Counts and Characteristics of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor or Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor Users with Type 2 Diabetes: A Descriptive Analysis
Descriptive
dipeptidyl peptidase-4 (DPP-4) inhibitors,
sodium-glucose cotransporter-2 (SGLT-2) inhibitors
Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease: An Inverse Probability of Treatment Weighting Analysis
Retrospective Inferential
serious infection
Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: An Updated Descriptive Analysis
Descriptive
Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: An Updated Descriptive Analysis
TriNetX Analysis
new molecular entities (NMEs)
Utilization of Beta Blockers in the Pediatric Population: A Follow Up Updated Descriptive Analysis
Descriptive
Concomitant Use of Medications with Drug-Drug Interactions with Nirmatrelvir and Ritonavir Among Patients Treated with Nirmatrelvir and Ritonavir or Patients with COVID-19: A Descriptive Analysis
Descriptive
nirmatrelvir and ritonavir
Utilization of Ibrexafungerp in Pregnant Patients: An Updated Descriptive Analysis in TriNetX
TriNetX Analysis
Duration of Follow Up for New Molecular Entities Approved in 2007: A Descriptive Analysis
Summary Table
new molecular entities (NMEs)
Interstitial Lung Disease (ILD) in Patients with Inflammatory Bowel Disease (IBD) and Following Vedolizumab or Natalizumab Initiation: A Descriptive Analysis
Descriptive
natalizumab,
vedolizumab
interstitial lung disease
Interstitial Lung Disease (ILD) Rates in Patients with Inflammatory Bowel Disease (IBD) and Following IBD Advanced Therapy: A Descriptive Analysis
Descriptive
adalimumab,
certolizumab,
etrasimod,
golimumab,
infliximab,
mirikizumab,
ozanimod,
risankizumab,
tofacitinib,
upadacitinib,
ustekinumab
interstitial lung disease
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: An Interrupted Time Series Analysis
Retrospective Inferential
Validation of Hospitalized COVID-19 Diagnosis Detected from Claims-Based Algorithms: A Descriptive Analysis
Site-Specific Query
Utilization of Products Over Time for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Descriptive
products for the development of the pregnancy safety study framework
use in pregnancy
Utilization of Loop Diuretics: A Descriptive Analysis
Descriptive
bumetanide,
loop diuretics
Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis
TriNetX Analysis
new molecular entities (NMEs)
Count and Duration of Follow-up of New-Onset Cancer: A Descriptive Analysis
Descriptive
Intentional Self-Harm Following Montelukast Use in Patients with Asthma: An Updated Analysis Using ICD-10-CM Coding
Retrospective Inferential
inhaled corticosteroids,
montelukast
intentional self-harm
Arterial and Venous Thrombotic Events in Patients with COVID-19 in Inpatient and Ambulatory Settings: A Descriptive Analysis
Descriptive
arterial thromboembolism
venous thromboembolism
Racial and Ethnic Differences in the Clinical Characteristics of Patients with Various Stages of COVID-19: A Descriptive Analysis
PCORnet Descriptive Analysis
Utilization and Coding Patterns of Long-Acting Injectable Antipsychotics (LAIA): A Descriptive Analysis
Descriptive
long-acting injectable antipsychotics
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: An Updated Descriptive Analysis
Descriptive
Gimoti (metoclopramide nasal spray)
Characterization of Gimoti (Metoclopramide Nasal Spray) Dispensing Patterns: A Descriptive Analysis
Descriptive
Gimoti (metoclopramide nasal spray)
Ustekinumab and Comparator Treatment Utilization and Pneumonia Outcomes in Patients with Crohn's Disease or Ulcerative Colitis: An Updated Descriptive Analysis
Descriptive
adalimumab,
infliximab,
ustekinumab,
vedolizumab
pneumonia (Chron's disease)
pneumonia (ulcerative colitis)
Capture of Long COVID in TriNetX: A Descriptive Analysis
TriNetX Analysis
post-acute COVID-19 syndrome
Occurrence of Stroke, Intracranial Hemorrhage, and Bleeding Outcomes Following Direct Oral Anticoagulant Use in Patients Aged 64 or Younger with Atrial Fibrillation: A Descriptive Analysis
Descriptive
apixaban,
dabigatran,
edoxaban,
rivaroxaban
gastrointestinal bleeding
intracranial hemorrhage
major extracranial bleeding
thromboembolic stroke
Counts and Characteristics of Long-Acting Injectable Antipsychotic (LAIA) Users: A Descriptive Analysis
Descriptive
long-acting injectable antipsychotics
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients with Diabetes Mellitus: A Descriptive Analysis
Descriptive
Outcome Monitoring Following Dupilumab Use: A Signal Identification Analysis
Signal Identification
Mixed Amphetamine Salts Immediate-Release Tablet Use: A Descriptive Analysis
Descriptive
mixed amphetamine salts immediate-release tablets
Outcome Monitoring Following Baloxavir Use: A Signal Identification Analysis
Signal Identification
Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non-Melanoma Skin Cancer: A Descriptive Analysis
Descriptive
Medication Use Among Pregnant Patients With COVID-19: A Descriptive Analysis
Descriptive
Utilization of Drug-Device or Biologic-Device Combinations: A Descriptive Analysis
Descriptive
Lipiodol (Ethiodized Oil) and Other Non-Oil Based Iodine Imaging Agent Utilization Patterns: A Descriptive Analysis
Descriptive
Lipiodol (ethiodized oil)
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis
Descriptive
brodalumab,
guselkumab,
risankizumab,
tildrakizumab
Counts and Characteristics of Pegylated Liposomal Doxorubicin and Non-Liposomal Doxorubicin Users: A Descriptive Analysis
Descriptive
non-liposomal doxorubicin,
pegylated liposomal doxorubicin
Characterization of Cannabis-Derived Product Users in the National Patient-Centered Clinical Research Network (PCORnet): A Descriptive Analysis
PCORnet Descriptive Analysis
cannabis-derived products
Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Retrospective Inferential
armodafinil,
modafinil
non-cardiac congenital malformations
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) That Employ Elements to Assure Safe Use (ETASU): A Descriptive Analysis
Descriptive
alosetron,
alvimopan,
clozapine,
collagenase clostridium histolyticum,
denosumab,
eculizumab,
idelalisib,
isotretinoin,
lenalidomide,
mifepristone,
mycophenolate,
natalizumab,
olanzapine extended release,
panobinostat,
phentermine/​topiramate,
pomalidomide,
romiplostim,
teduglutide,
testosterone undecanoate,
vigabatrin
Racial and Ethnic Differences in COVID-19 Treatment and Mortality in TriNetX: A Descriptive Analysis
TriNetX Analysis
Utilization, Dispensing, and Coding Patterns of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Neulasta (pegfilgrastim),
Neupogen (filgrastim),
Remicade (infliximab)
COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis
Retrospective Inferential
proton pump inhibitors
COVID-19 hospitalization
Severe COVID-19
Characterization of Use of Biologics and Biosimilars in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Neupogen (filgrastim),
Remicade (infliximab)
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis
Descriptive
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers Linked to Live-Birth Deliveries in the Mother-Infant Linkage Table: A Descriptive Analysis
Descriptive
products for the development of the pregnancy safety study framework
use in pregnancy
Utilization of Products for the Development of the Pregnancy Safety Study Framework Among Mothers with Live-Birth Deliveries: A Descriptive Analysis
Descriptive
products for the development of the pregnancy safety study framework
use in pregnancy
Baloxavir and Oseltamivir Utilization: A Descriptive Analysis
Descriptive
baloxavir,
oseltamivir
Bevacizumab and Other Cancer Medication Use in Pregnant Patients: A Descriptive Analysis
Summary Table
bevacizumab,
pegaptanib,
ranibizumab,
verteporfin
Incident Utilization of Allopurinol, Hydralazine, and Propylthiouracil: A Descriptive Analysis
Summary Table
allopurinol,
hydralazine,
propylthiouracil
Incident Utilization Patterns of Obesity Drugs: A Descriptive Analysis
Summary Table
Utilization and Switching Patterns of Mixed Amphetamine Salt (MAS) Products in Patients with Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy: A Descriptive Analysis
Descriptive
mixed amphetamine salts
switching patterns
Utilization of Beta Blockers in the Pediatric Population: An Updated Descriptive Analysis
Descriptive
Utilization of Beta Blockers in the Pediatric Population: A Descriptive Analysis
Descriptive
Characterization of Cannabis-Derived Product Users in TriNetX: Five Descriptive Analyses
TriNetX Analysis
cannabis-derived products
Baricitinib or Tocilizumab Use in Hospitalized Patients with a COVID-19 Diagnosis: A Descriptive Analysis
PCORnet Descriptive Analysis
baricitinib,
tocilizumab
emergency use authorization (EUA) utilization
Prevalence and Characterization of Pharmacogenetic Testing Healthcare Common Procedure Coding System (HCPCS) Procedure Codes in the Mini-Sentinel Distributed Database (MSDD): A Descriptive Analysis
Summary Table
pharmacogenetic testing
Dupixent (Dupilumab) Utilization Patterns: A Descriptive Analysis
Descriptive
Alosetron and Eluxadoline Use: A Descriptive Analysis
Descriptive
alosetron,
eluxadoline
Renal Cell Carcinoma Following Canagliflozin Use in Patients with Type 2 Diabetes: A Descriptive Analysis
Descriptive
renal cell carcinoma
Outcome Monitoring Following Erenumab Use: A Signal Identification Analysis
Signal Identification
Mortality Following Long-Acting Injectable Antipsychotics Use in Patients with Dementia: An Inverse Probability of Treatment Weighting Analysis
Retrospective Inferential
long-acting injectable antipsychotics
Biologics Use in Adults with Ulcerative Colitis: A Descriptive Analysis
Descriptive
adalimumab,
golimumab,
infliximab,
vedolizumab
Ischemic Colitis Following Alosetron Use: A Descriptive Analysis
Descriptive
ischemic colitis
Utilization and Switching Patterns of Inhaled Corticosteroid/Long Acting Beta Agonist and Advair Diskus in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Descriptive Analysis
Descriptive
Advair Diskus,
fluticasone salmeterol
brand to generic switching
Brand to Generic Switching Patterns Among Advair Diskus Users with Asthma or Chronic Obstructive Pulmonary Disease (COPD): A Descriptive Analysis
Descriptive
Advair Diskus,
fluticasone salmeterol
brand to generic switching
Insulin Coding Practices: A Descriptive Analysis
Descriptive
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis
Retrospective Inferential
sacubitril/​valsartan
Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis
Retrospective Inferential
sacubitril/​valsartan
Utilization of Select Products for Migraine Treatment and Prevention: A Descriptive Analysis
Descriptive
eptinezumab,
erenumab-aooe,
fremanezumab,
galcanezumab,
rimegepant,
ubrogepant
Utilization of Select Biological Products: A Descriptive Analysis
Descriptive
Avastin (bevacizumab),
Epogen (epoetin alfa),
Inflectra (infliximab-dyyb),
Mvasi (bevacizumab-awwb),
Neupogen (filgrastim),
Remicade (infliximab),
Renflexis (infliximab-abda),
Retacrit (epoetin alfa-epbx),
Zarxio (filgrastim-sndz),
Zirabev (bevacizumab-bvzr)
Outcome Monitoring Following Zarxio Use: An Updated Signal Identification Analysis
Signal Identification
Zarxio (filgrastim-sndz)
Congenital Malformations Observed in the Mother’s or Linked Infant’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis
Descriptive
all congenital malformations
congenital cardiac malformations (primary)
congenital urinary malformations (primary)
Congenital Malformations Observed in the Mother’s Records Following Fingolimod Use During Pregnancy: A Descriptive Analysis
Descriptive
all congenital malformations
congenital cardiac malformations (primary)
congenital urinary malformations (primary)
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: A Descriptive Analysis
Descriptive
atrioventricular block
heart failure
permanent pacemaker placement
septal myectomy
ventricular arrhythmia
Cardiovascular Outcomes Following Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) Procedures: An Updated Descriptive Analysis
Descriptive
atrioventricular block
heart failure
myocardial infarction
permanent pacemaker placement
septal myectomy
ventricular arrhythmia
Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis
TriNetX Analysis
Identifying Potential Risk Factors for Respiratory Failure: A Covariate Stratified Analysis
Retrospective Inferential
acute respiratory failure
Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis
Descriptive
acute respiratory failure
Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis
Descriptive
Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis
Signal Identification
Ozempic (semaglutide)
Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis
Signal Identification
Zarxio (filgrastim-sndz)
Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX
TriNetX Analysis
Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis
Retrospective Inferential
any fracture
hip replacement
major fracture (primary)
temporomandibular joint replacement
Fractures Following Leuprolide Acetate Use: A Multiple Factor Matched Analysis (A Follow-up to a Previous Analysis)
Retrospective Inferential
any fracture
hip replacement
major fracture (primary)
temporomandibular joint replacement
Comparative Effectiveness of Azithromycin Relative to Roflumilast in Individuals With Uncontrolled Chronic Obstructive Pulmonary Disease Despite Triple Inhaled Therapy
azithromycin,
roflumilast
hospitalization and death
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
casirivimab imdevimab
Differences in COVID-19 Testing, Positivity, Hospitalization, and Mortality by Race and Ethnicity in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Utilization of Obesity Drugs: A Descriptive Analysis
Descriptive
Hospitalization and Anaphylaxis Following Monoclonal Antibodies (mAb) Use in Patients with COVID-19: A Descriptive Analysis
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
casirivimab imdevimab,
sotrovimab
anaphylaxis
hospitalization
Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis
Summary Table
obesity drugs,
sodium-glucose co-transporter-2 (SGLT-2) inhibitor
Characterization of Infants in the Mother-Infant Linkage Table in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Seizures Following Gadolinium-Based Contrast Agents Exposure: A Self-Controlled Risk Interval Analysis
Retrospective Inferential
gadolinium-based contrast agents (GBCA)
Tacrolimus Use in Patients Following Liver or Kidney Transplants: A Descriptive Analysis
Descriptive
Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: A Descriptive Analysis
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
casirivimab imdevimab
Count and Duration of Follow-up of New-Onset Cancer: An Updated Descriptive Analysis
Descriptive
Characterizing Pregnant Women With and Without Evidence of Heart Failure and Non-Pregnant Women With Heart Failure: A Propensity Score Matched Analysis
Retrospective Inferential
Bamlanivimab, Bamlanivimab and Etesevimab, and Casirivimab-Imdevimab Use in Patients with COVID-19: A Descriptive Analysis
Descriptive
bamlanivimab,
bamlanivimab etesevimab,
casirivimab imdevimab
Outpatient Corticosteroid Use in Patients With COVID-19: An Updated Descriptive Analysis
Descriptive
Outpatient Corticosteroid Use in Patients With COVID-19: A Descriptive Analysis
Descriptive
Serious Infection Following Ustekinumab Use in Patients with Crohn’s Disease or Ulcerative Colitis: A Descriptive Analysis
Descriptive
adalimumab,
infliximab,
ustekinumab,
vedolizumab
serious infection (Crohn’s disease)
serious infection (ulcerative colitis)
Characterization of Pediatric Demographics and Enrollment in the Sentinel Distributed Database: A Descriptive Analysis
Descriptive
Death Data Exploration: A Descriptive Analysis
Custom Code
Thromboembolic Stroke, Major Extracranial Bleeding, Gastrointestinal Bleeding, and Intracranial Hemorrhage following Direct Oral Anticoagulant Use in Patients Aged 65 or Older: An Inverse Probability of Treatment Weighting (IPTW) Analysis
Retrospective Inferential
apixaban,
dabigatran,
rivaroxaban
gastrointestinal bleeding
intracranial hemorrhage
major extracranial bleeding
thromboembolic stroke
Incidence and Prevalence of Confounding Variables Over Time in the Sentinel Distributed Database (SDD): A Descriptive Analysis
Descriptive
Duration of Follow Up for New Molecular Entities Approved in 2018: First Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Counts and Characteristics of Individuals 25 Years Old or Younger With Drug-Device or Biologic-Device Combination Use: A Descriptive Analysis
Descriptive
drug device combinations
Utilization of Brodalumab: A Descriptive Analysis
Descriptive
Estimated Prevalence of Glomerular Diseases: An Updated Descriptive Analysis
Descriptive
glomerular diseases
Estimated Prevalence of Glomerular Diseases: A Descriptive Analysis
Descriptive
glomerular diseases
Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis
Descriptive
Epidiolex (Prescription Cannabidiol) Utilization Patterns: A Descriptive Analysis
Descriptive
Epidiolex (prescription cannabidiol)
Valganciclovir Use in Children with Congenital Cytomegalovirus Disease (cCMV) or Cytomegalovirus (CMV) Infection: A Descriptive Analysis
Descriptive
Incident and Prevalent Use of Loop Diuretics: A Descriptive Analysis
Descriptive
Human Epidermal Growth Factor Receptor 2 (HER2) Antagonist Use in Patients with Live Birth Deliveries: A Descriptive Analysis
Descriptive
Drug Utilization Over Time for Six Drug Classes
Descriptive
ace inhibitors,
beta blockers,
granulocyte colony-stimulating factor (GC-SF),
intravenous (IV) iron,
statins,
tumor necrosis factor (TNF) alpha inhibitor
Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis
Descriptive
mometasone sinus implant
Incidence and Prevalence of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Contaminated Valsartan Use: A Descriptive Analysis
Descriptive
Bleeding Events and Venous Thromboembolism (VTE) following Enoxaparin Use: A Descriptive Analysis
Descriptive
hospitalized bleeding
major bleeding
venous thromboembolism (VTE)
Tofacitinib, Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Tumor Necrosis Factor Inhibitors (TNFi) Use: A Descriptive Analysis
Descriptive
disease-modifying anti-rheumatic drugs (DMARDs),
tofacitinib,
tumor necrosis factor inhibitors (TNFi)
N‐nitrosodimethylamine (NDMA)‐Contaminated and Non‐NDMA‐Contaminated Valsartan Use: A Descriptive Analysis
Descriptive
Duration of Follow Up for New Molecular Entities Approved in 2019: First Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2017: Second Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis
Retrospective Inferential
hospitalized depression
intentional self-harm
Intentional Self-Harm and Hospitalized Depression Following Sertraline Use: A Propensity Score Matched Analysis (A Follow-up to a Previous Analysis)
Retrospective Inferential
hospitalized depression
intentional self-harm
Racial Differences in COVID-19 Outcomes (2020-2021)
Retrospective Inferential
Critical COVID-19
death
hospitalization with COVID-19
Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis
Descriptive
alemtuzumab,
cladribine,
dalfampridine,
dimethyl fumarate,
diroximel fumarate,
fingolimod,
glatiramer acetate,
interferon beta-1A,
interferon beta-1B,
mitoxantrone,
natalizumab,
ocrelizumab,
peginterferon beta-1a,
siponimod,
teriflunomide
Oral Metoclopramide Use: A Descriptive Analysis
Descriptive
Utilization of Drugs with Approved Risk Evaluation and Mitigation Strategies (REMS) That Employ Elements to Assure Safe Use (ETASU)
Summary Table
drugs with REMS that employ ETASU
Duration of Follow Up for New Molecular Entities Approved in 2017: First Descriptive Analysis
Descriptive
new molecular entities (NMEs)
Brand and Generic Tacrolimus Use following Kidney, Heart, and Liver Transplants: A Descriptive Analysis
Descriptive
Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis
Descriptive
apixaban,
dabigatran,
oral anticoagulant,
rivaroxaban,
warfarin
severe uterine bleed
Utilization of Sacubitril/Valsartan: A Descriptive Analysis
Descriptive
sacubitril/​valsartan
Duration of Follow Up for New Molecular Entities Approved in 2011
Descriptive
new molecular entities (NMEs)
Patterns in Insulin Product Use and Billing Codes: A Descriptive Analysis
Descriptive
Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015
Descriptive
new molecular entities (NMEs)
Duration of Follow Up for New Molecular Entities Approved in 2016
Descriptive
new molecular entities (NMEs)
Follow-Up Time for Guselkumab, Risankizumab, and Tildrakizumab Users with Plaque Psoriasis: First Descriptive Analysis
Descriptive
guselkumab,
risankizumab,
tildrakizumab